FDA Approves Daratumumab and Hyaluronidase-fihj With Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

On January 27, the FDA approved daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

For more information, read the FDA announcement and the Johnson & Johnson press release.

Posted on 1/30/2026